Aktienanalyse zu AxoGen, Inc. (AXGN)AXGNAxoGen, Inc.

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

AxoGen Inc is not a strong buy right now due to its current price of $36.13, which is significantly below the average analyst price target of $55. However, the stock has seen a substantial 131.75% increase over the past year, indicating strong long-term growth potential. The RSI is at a very low 11.186, suggesting it may be oversold, but the recent insider selling has increased by 768.09%, which raises concerns about confidence in the stock. The main risk is the forward P/E ratio of 102.04, indicating that the stock may be overvalued relative to its earnings expectations. Therefore, while there is potential for recovery, caution is advised before making a purchase.

6 analysts cover AXGN: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.80.